The global Liposome and Microsphere Delivery System market size is predicted to grow from US$ 5123 million in 2025 to US$ 11040 million in 2031; it is expected to grow at a CAGR of 13.7% from 2025 to 2031.

Liposomes and microspheres are two widely used technologies for drug delivery, each with its own advantages and characteristics. Liposomes are based on phospholipid bilayers and can encapsulate both hydrophilic and hydrophobic drugs, which are highly biocompatible and highly targeted, and are commonly used in cancer therapy, vaccines and anti-infective drugs, but their stability and cost limit their further popularization; microspheres, which are usually made of biodegradable polymers, specialize in long-lasting and controlled release, and are widely used in the treatment of chronic diseases and the delivery of vaccines, but the rate of drug release is greatly affected by the environment. However, the rate of drug release is strongly influenced by the environment. This study will focus on two biotechnologies: liposomes and microspheres.
United States market for Liposome and Microsphere Delivery System is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Liposome and Microsphere Delivery System is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Liposome and Microsphere Delivery System is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Liposome and Microsphere Delivery System players cover Gilead Sciences Ltd, Pacira, Shandong Luye Pharmaceutical Co., Ltd., Sun Pharmaceutical, Johnson & Johnson, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LP Information, Inc. (LPI) ' newest research report, the “Liposome and Microsphere Delivery System Industry Forecast” looks at past sales and reviews total world Liposome and Microsphere Delivery System sales in 2024, providing a comprehensive analysis by region and market sector of projected Liposome and Microsphere Delivery System sales for 2025 through 2031. With Liposome and Microsphere Delivery System sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Liposome and Microsphere Delivery System industry.

This Insight Report provides a comprehensive analysis of the global Liposome and Microsphere Delivery System landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Liposome and Microsphere Delivery System portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Liposome and Microsphere Delivery System market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Liposome and Microsphere Delivery System and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Liposome and Microsphere Delivery System.

This report presents a comprehensive overview, market shares, and growth opportunities of Liposome and Microsphere Delivery System market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

    Powder
    Preparation

Segmentation by Application:

    Drug Delivery
    Vaccine Development
    Diagnostic Imaging

This report also splits the market by region:

    Americas

        United States
        Canada
        Mexico
        Brazil

    APAC

        China
        Japan
        Korea
        Southeast Asia
        India
        Australia

    Europe

        Germany
        France
        UK
        Italy
        Russia

    Middle East & Africa

        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

    Gilead Sciences Ltd
    Pacira
    Shandong Luye Pharmaceutical Co., Ltd.
    Sun Pharmaceutical
    Johnson & Johnson
    Leadiant Biosciences (Sigma-Tau)
    Ipsen (Onivyde)
    Teva Pharmaceutical
    Novartis
    Lipoid
    Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
    Shanghai SPH New ASIA Pharmaceutical Co., Ltd.
    China Pharmaceutical Holding Group Co., Ltd.
    Changzhou Jinyuan Pharmaceutical Co., Ltd.
    FormuMax Scientific, Inc.
    Oakwood Labs
    Fuisz Technologies Ltd
    Delpharm
    Terumois
    Powder Systems Limited
    PolyMicrospheres
    AULBIO
    Shanghai Livzon Pharmaceutical Co., Ltd.
    Beijing Biote Pharmaceutical Co., Ltd.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Liposome and Microsphere Delivery System market?
What factors are driving Liposome and Microsphere Delivery System market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Liposome and Microsphere Delivery System market opportunities vary by end market size?
How does Liposome and Microsphere Delivery System break out by Type, by Application?